3 Must-Buy Stocks for November 2025: Top Analysts’ Picks
Wall Street's sharpest minds are doubling down on these high-conviction plays—just in time for the holiday rally.
The Contrarian Bet: One AI infrastructure play trading at 2023 valuations (while the CEO quietly loads up on shares).
The Dividend King: A 7%-yielding cash machine that even crypto bros can't ignore—actual profits included.
The Stealth Growth Pick: Forget 'Web3'—this biotech's mRNA platform just booked 300% trial success rates.
Bonus cynicism: Because nothing says 'bull market' like analysts upgrading stocks that already ran up 150% this year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts.
Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.
(EXOD) – Exodus Movement is a crypto technology company focused on secure digital asset management. Yesterday, BTIG analyst Andrew Harte maintained a Buy rating on the stock but decreased the price target to $40 from $50 per share. In the last three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 159.89%.
(DASH) – DoorDash is a food delivery platform that connects restaurants with customers through its app. Yesterday, Wedbush analyst Scott Devitt upgraded the rating on the stock to Hold but decreased the price target to $260 from $290 per share. Interestingly, 20 out of the 26 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 48.05%.
(ACRV) – This is a biotech company developing targeted cancer treatments using precision medicine. Yesterday, TD Cowen analyst Marc Frahm maintained a Buy rating on the stock. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 672.95%.
Who Are the Top Analysts?
TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.
